

Express Mail No.: EV416037106US

Deposited On: 09/29/2006

10-02-06

IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

Total Number of Pages in This Submission

Application Number

10/774,242

Filing Date

02/06/2004

First Named Inventor

Patrick A. McKee et al.

Art Unit

1653

Examiner Name

Hope A. Robinson

Attorney Docket Number

5820.646

ENCLOSURES (Check all that apply)

☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment/Reply

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☒

Information Disclosure Statement

☐

Certified Copy of Priority Document(s)

☐

Reply to Missing Parts/Incomplete Application

☐

Reply to Missing Parts under 37 CFR 1.52 or 1.53

☐

Drawing(s)

☐

Licensing-related Papers

☐

Petition

☐

Petition to Convert to a Provisional Application

☐

Power of Attorney, Revocation of POA, Change of Correspondence Address

☐

Terminal Disclaimer

☐

Request for Refund

☐

CD, Number of CD(s) _____

☐

Landscape Table on CD

☐

After Allowance Communication to TC

☐

Appeal Communication to Board of Appeals and Interferences

☐

Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)

☐

Proprietary Information

☐

Status Letter

☒

Other Enclosure(s) (please identify below):

See Remarks

Remarks

1. Transmittal (1 page);
2. 2nd Supplemental Information Disclosure Statement (Filed Under 37 C.F.R. 1.97(e)(1))(3 pages);
3. 2nd Supplemental Form PTO-1449 (2 pages);
4. Copies of cited material; and
5. Return Receipt Postcard.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

DUNLAP, CODDING & ROGERS, P.C.

Signature

Printed name

Christopher W. Corbett

Date

09/29/2006

Reg. No.

36,109

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: *** SENT BY EXPRESS MAIL DATED 09/29/2006 ***

Signature

Typed or printed name

Christopher W. Corbett

Date

09/29/2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EXPRESS MAIL NO.: EV416037106US
Deposited On: September 29, 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/774,242 Confirmation No.: 8624
Applicant(s) : Patrick A. McKee, Kyung N. Lee,
Kenneth W. Jackson and Victoria J. Christiansen
Filed : 02/06/2004
TC/Au : 1653
Examiner : Hope A. Robinson
Title : ANTIPLASMIN CLEAVING ENZYME
Docket No. : 5820.646
Customer No. : 30589

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

2nd SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
(FILED UNDER 37 C.F.R 1.97(e)(1))

List of Sections Forming Part of This
Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Statement Under 37 C.F.R. 1.97(e)(1)
2. ☒ Preliminary Statements
3. ☒ FORM PTO-1449 (Modified)
4. ☐ Statement as to Information Not Found in Patents or Publications
5. ☒ Copies of Listed Information Items Accompanying this Statement

6. ☒ Identification of Person(s) Making this Information Disclosure Statement

Section 1. Statement Under 37 C.F.R. 1.97(e)(1)

Each item in the information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Supplemental Information Disclosure Statement therefore, no fee is required.

Section 2. Preliminary Statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Section 3. Form PTO-1449 (Modified)

☒ A completed Form 1449 (Modified) is attached hereto.

☐ No Form 1449 (Modified) is attached.

Section 4. Statement as to Information Not Found in Patents or Publications (Information Not Listed in Form PTO-1449)

Section 5. Copies of Listed Information Items Accompanying this Statement

Legible copies of all items listed in Form PTO-1449 (Modified) accompany this information disclosure statement.

Section 6. Identification of Person(s) Making this INFORMATION DISCLOSURE STATEMENT

The person making this statement is the attorney who signs below on the basis of the information:

- ☐ [] supplied by the inventor(s)
- ☐ [] supplied by an individual associated with the filing and prosecution of this application (37 C.F.R. § 1.56(c)).
- ☐ [] in the attorney's file
- ☒ [X] provided in the International Search Report cited herein

Respectfully submitted,



Christopher W. Corbett, Reg. No. 36,109
DUNLAP, CODDING & ROGERS, P.C.
P.O. Box 16370
Oklahoma City, Oklahoma 73113
(405) 607-8600 - telephone
(405) 607-8686 - telefax

Agent for Applicant(s)

Express Mail:EV416037106US
Date Deposited: 09/29/2006



Page 1 of 2

Substitute for form 1449A/PTO

**2nd SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known	
Application Number	10/774,242
Filing Date	02/06/2004
First Named Inventor	Patrick A. McKee et al.
Group Art Unit	1653 (conf. No. 8624)
Examiner Name	Hope A. Robinson
Attorney Docket Number	5820.646

U. S. PATENT DOCUMENTS

EXAM INIT.	Cite No. 1	U.S. PATENT NUMBER Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

EXAM INIT.	Cite No. 1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office 3	Number 4	Kind Code ⁵ (if known)				
			EP 04 70 9157		McKee (Supplementary EPO Search Report)	08/16/2006		
			WO 97/34927 A		Zimmerman et al. (Ludwig Institute for Cancer Research)	09/27/1997		

U.S. and Foreign: ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴Form Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

EXAM INIT.	PATENT DOCUMENTS	
	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
	FOEKENS ET AL., "The Prognostic Value of Polymorphonuclear Leukocyte Elastase in Patients with Primary Breast Cancer", <i>Cancer Research</i> , Vol. 63, No. 2 (Jan. 15, 2003) pp. 337-341. (XP-002394318)	

EXAM INIT.	<p style="text-align: center;">PATENT DOCUMENTS</p> <p style="text-align: center;">Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published</p>	
		LEE ET AL., "A novel plasma proteinase potentiates α_2 -antiplasmin inhibition of fibrin digestion", <i>Blood</i> , Vol. 103, No. 10 (May 15, 2004) pp. 3783-3788. (XP-002394321)
		LEE ET AL., "Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein", <i>Blood</i> , Vol. 107, No. 4 (Feb. 15, 2006) pp. 1397-1404. (XP-002394322)
		PARK ET AL., "Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fobroblasts", <i>Journal of Biological Chemistry</i> , Vol. 274, No. 51 (Dec. 17, 1999) pp. 36505-36512. (XP-002163938)
		URANO ET AL., "The cleavage and inactivation of plasminogen activator inhibitor type 1 and α_2 -antiplasmin by reptilase, a thrombin-like venom enzyme", <i>Blood Coagulation and Fibrinolysis 2000</i> , Vol. 11, No. 2 (March 2000) pp. 145-153. (XP009071038)
Non Patent Documents: ¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.		
Examiner Signature:		Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant. **Place of Publication refers to name of publication in which the information was published.		